With the acquisition, Nexus will be adding to its current operations in the US and Germany the REMP operations in Switzerland, Germany, Japan and the US.

In addition, REMP provides additional R&D, manufacturing, sales and customer support operations in Switzerland and direct sales and customer support in Kawasaki, Japan.

Nexus Biosystems CEO John Lillig said that together, with their new REMP colleagues, they look forward to continuing to provide sample management solutions to their biopharmaceutical, biorepository, diagnostic, forensic, agrochemical and genomic research customers around the world.

“The combined Nexus-REMP resources will strengthen our overall capabilities with expanded first-class service and support for our worldwide customers and a growing pipeline of new product offerings for the growing global sample management community,” Lillig said.